Coeptis Therapeutics Holdings Inc
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
ZSQR$2.30-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended | ||
|---|---|---|
| March 31, 2024 | March 31, 2023 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(3,001,388) | $(7,957,833) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 250,211 | 250,309 |
| Amortization of debt discount | 150,000 | – |
| Change in fair value of derivative liability warrants | (34,875) | 1,387,500 |
| Stock based compensation | 96,889 | 122,391 |
| Shares issued for non-employee services | 541,750 | 2,396,814 |
| Shares subscribed for non-employee services | – | 720,000 |
| Warrants issued for extinguishment of debt | – | 1,111,706 |
| Warrants issued for services | 8,150 | – |
| (Increase) decrease in: | ||
| Accounts receivable | – | 8,075 |
| Interest receivable | (69,604) | – |
| Prepaid assets | 47,140 | 20,709 |
| Right of use asset/liability | 45 | (208) |
| Increase (decrease) in: | ||
| Accounts payable | (53,801) | 143,432 |
| Accrued expenses | 163,093 | 112,635 |
| NET CASH USED IN OPERATING ACTIVITIES | (1,902,390) | (1,684,470) |
| INVESTING ACTIVITIES | ||
| Notes receivable | (100,000) | – |
| NET CASH USED IN INVESTING ACTIVITIES | (100,000) | – |
| FINANCING ACTIVITIES | ||
| Proceeds from notes payable | 1,350,000 | – |
| Repayment of notes payable | (287,500) | – |
| Shares issued for cash | 500,000 | – |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 1,562,500 | – |
| NET DECREASE IN CASH | (439,890) | (1,684,470) |
| CASH AT BEGINNING OF PERIOD | 1,469,134 | 3,791,302 |
| CASH AT END OF PERIOD | $1,029,244 | $2,106,832 |
| SUPPLEMENTAL DISCLOSURES | ||
| Shares exchanged for note receivable | $1,900,000 | – |
| Interest paid | $– | $– |
| Taxes paid (refunded) | $– | $– |
COEPTIS THERAPEUTICS HOLDINGS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.